Warchol Stanislaw, Krzemien Grazyna, Szmigielska Agnieszka, Bombinski Przemyslaw, Brzewski Michal, Dudek-Warchol Teresa
Department of Paediatric Surgery and Urology, Medical University of Warsaw, Warsaw, Poland.
Department of Paediatrics and Nephrology, Medical University of Warsaw, Warsaw, Poland.
J Pediatr Urol. 2016 Aug;12(4):256.e1-4. doi: 10.1016/j.jpurol.2016.04.006. Epub 2016 May 10.
Endoscopic correction of vesicoureteral reflux (VUR) in children offers minimally invasive management and is widely used as a first-line procedure for all grades of reflux. However, there is debate about which tissue-augmenting substance is the best to use. The aim of this study was to evaluate the efficacy of two bulking substances, Deflux (Dx/HA) and Vantris (PPC), for endoscopic treatment of VUR in children.
From 2009 to 2012, 65 children (50 girls and 15 boys) aged 1.45-9.9 years (mean 4.85 ± 2.52) underwent endoscopic correction of VUR using Deflux. VUR was unilateral in 31 patients and bilateral in 34 patients, comprising 108 renal refluxing units (RRUs) grades: II in 52, III in 47, IV in 7, and V in 2. From 2012, 68 children (43 girls and 25 boys) aged 0.6-17.9 years (mean 4.89 ± 3.46) were treated with Vantris. VUR was unilateral in 33 and bilateral in 35 patients, comprising 109 RRUs grades: II in 48, III in 29, IV in 13, and V in 19. Voiding cystourethrogram was done 3 months after procedure.
All patients completed follow-up (summary Table). With Deflux, reflux resolved in almost 93% of RRUs after two procedures (in 63% after first injection), with Vantris, VUR was corrected in the same percentage after one procedure.
The success rate with Deflux ranges between 68% and 92% (only 50-70% after single injection). The reported possibility of reflux recurrence after successful Deflux treatment, and the need for repeated injection led to introduction of the new substance Vantris. The results of a multi-centre survey published in 2014 showed that reflux is corrected in more than 90% of cases after single PPC injection. Our results with PPC confirm a high level of reflux resolution.
Our data show that Vantris injection is a safe and effective procedure for treating all grades of VUR with good clinical outcome, and provides a higher and almost complete level of reflux resolution after first injection compared with Deflux.
儿童膀胱输尿管反流(VUR)的内镜矫正提供了微创治疗,被广泛用作所有等级反流的一线治疗方法。然而,关于使用哪种组织填充物质最佳存在争议。本研究的目的是评估两种填充物质Deflux(Dx/HA)和Vantris(PPC)用于儿童VUR内镜治疗的疗效。
2009年至2012年,65名年龄在1.45 - 9.9岁(平均4.85±2.52岁)的儿童(50名女孩和15名男孩)接受了使用Deflux的VUR内镜矫正。31例患者为单侧VUR,34例为双侧VUR,共108个肾反流单位(RRUs),分级为:II级52个,III级47个,IV级7个,V级2个。从2012年起,68名年龄在0.6 - 17.9岁(平均4.89±3.46岁)的儿童(43名女孩和25名男孩)接受了Vantris治疗。33例患者为单侧VUR,35例为双侧VUR,共109个RRUs,分级为:II级48个,III级29个,IV级13个,V级19个。术后3个月进行排尿膀胱尿道造影。
所有患者均完成随访(汇总表)。使用Deflux时,两次操作后几乎93%的RRUs反流消失(首次注射后63%),使用Vantris时,一次操作后VUR以相同百分比得到矫正。
Deflux的成功率在68%至92%之间(单次注射后仅50 - 70%)。已报道Deflux成功治疗后反流复发的可能性以及重复注射的必要性促使了新物质Vantris的引入。2014年发表的一项多中心调查结果显示,单次PPC注射后超过90%的病例反流得到矫正。我们使用PPC的结果证实了较高的反流消除水平。
我们的数据表明,Vantris注射是治疗所有等级VUR的安全有效方法,临床效果良好,与Deflux相比,首次注射后能提供更高且几乎完全的反流消除水平。